Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 5/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313545 | 0.95 | FGFR1 (0.59) | FGFR1SYKPLK1PTK2PTK2B | |
| SCHEMBL12234149 | 0.90 | PTK2 (0.50) | FGFR1PTK2PTK2BKCNH2ULK1 | |
| SCHEMBL13313544 | 0.89 | SYK (0.49) | FGFR1SYKPTK2PTK2BKCNH2 | |
| SCHEMBL12234940 | 0.86 | PTK2 (0.51) | PTK2PTK2BKCNH2ULK1EGFR | |
| SCHEMBL12235598 | 0.84 | ULK1 (0.60) | PTK2PTK2BKCNH2ULK1EGFR | |
| SCHEMBL15328911 | 0.84 | ULK1 (0.60) | PTK2PTK2BKCNH2ULK1EGFR | |
| SCHEMBL14616066 | 0.84 | ULK1 (0.60) | PTK2PTK2BKCNH2ULK1EGFR | |
| SCHEMBL3579714 | 0.84 | PTK2 (0.51) | PTK2PTK2BKCNH2ULK1 | |
| SCHEMBL4210144 | 0.83 | FGFR1 (0.51) | FGFR1SYKPLK1EGFR | |
| SCHEMBL3580189 | 0.83 | PTK2 (0.48) | SYKPTK2PTK2BKCNH2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008077885-A2 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | FGFR1 268/4885SYK 2935/4885PLK1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.